AIM 1/19 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 2/19 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 1/20 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 2/20 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 1/21 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 2/21 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 2/21-923 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 1/22 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 1/22-923 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 2/22 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 1/23 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 2/23 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 1/24 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 1/24 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
AIM 2/24 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)
APLA 1/19 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)
APLA 2/19 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)
APLA 1/20 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)
APLA 2/20 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)
APLA 1/21 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)
APLA 2/21 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)
APLA 1/22 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)
APLA 2/22 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)
APLA 1/23 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)
APLA 2/23 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)
APLA 1/24 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)
APLA 2/24 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)
IGIT 1/19 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)
IGIT 2/19 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)
IGIT 1/20 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA
IGIT 2/20 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA
IGIT 1/21 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA
IGIT 2/21 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA
IGIT 1/22 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA
IGIT 2/22 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA
IGIT 1/23 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA
IGIT 2/23 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA
IGIT 1/24 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA
RF 1/19 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)
RF 2/19 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)
RF 1/20 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)
RF 2/20 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)
RF 1/21 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)
RF 2/21 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)
RF 1/22 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)
RF 2/22 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)
RF 1/23 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)
RF 2/23 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)
RF 1/24 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)
RF 2/24 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)
PIG/19 Podtřídy IgG (IgG 4)
PIG/20 Podtřídy IgG (IgG 4)
IFT 1/16 Imunofenotypizace
IFT 2/2016 Imunofenotypizace
IFT 1/2017 Imunofenotypizace
IFT 2/2017 Imunofenotypizace
IFT 1/2018 Imunofenotypizace
IFT 2/2018 Imunofenotypizace
IFT 1/2019 Imunofenotypizace
IFT 2/2019 Imunofenotypizace
IFT 1/2020 Imunofenotypizace
IFT 2/2020 Imunofenotypizace
IFT 1/2021 Imunofenotypizace
IFT 2/2021 Imunofenotypizace
IFT 2/2022 Imunofenotypizace
IFT 1/2023 Imunofenotypizace
IFT 1/2023 Imunofenotypizace
IFT 2/2023 Imunofenotypizace
IFT 2/2023 Imunofenotypizace
IFT 1/2024 Imunofenotypizace
IFT 2/2024 Imunofenotypizace
T 1/22 Protilátky proti SARS-CoV-2 (studie)
Certifikát Autoimmunity 2021 – ANA
Certifikát Autoimmunity 2021 – ANCA
Certifikát Autoimmunity 2021 – Celiac
Certifikát Autoimmunity 2021 – DNA
Certifikát Autoimmunity 2023 – ANCA FINAL
Certifikát Autoimmunity 2023 – CELIAC FINAL
Certifikát Autoimmunity 2023 – Hep-2
Certifikát Autoimmunity 2024 – ANCA FINAL